Approaches to treating depression have relied on general inhibition of neurotransmitter reuptake, increasing the amount of time serotonin and other brain signaling molecules stay in the synaptic cleft in order to increase the intensity of their activity. However, those approaches are not necessarily specific to neurons involved in emotional state or behavior, and they also can produce side effects such as weight changes and sexual dysfunction. With its identification of a novel G protein-coupled neuroreceptor and drug candidates that selectively target the receptor